PMID- 23453501
OWN - NLM
STAT- MEDLINE
DCOM- 20130909
LR  - 20161209
IS  - 2213-0276 (Electronic)
IS  - 0755-4982 (Linking)
VI  - 42
IP  - 7-8
DP  - 2013 Jul-Aug
TI  - [Diagnosis and management of severe adverse events occurring during BCG therapy 
      for non-muscle invasive bladder cancer (NMIBC)].
PG  - 1100-8
LID - S0755-4982(13)00019-5 [pii]
LID - 10.1016/j.lpm.2012.10.017 [doi]
AB  - BCG therapy, which is the standard treatment for non-muscle invasive bladder 
      tumours with high risk of recurrence and progression, has potential 
      life-threatening adverse effects (AEs). Rapid deterioration of general condition 
      in a patient with history of bladder tumour should question about an ongoing 
      treatment with BCG and specify the date of the last instillation. Trauma during 
      catheterization and untreated concomitant urinary infection upon instillations 
      are risk factors of severe AEs. In emergency, the diagnosis of severe AEs of BCG 
      therapy is only based on the medical questioning with the notion of current BCG 
      treatment and risk-bearing event upon instillation. Management of AEs is related 
      to their pathophysiological mechanisms and relies on a combination of antibiotics 
      against BCG, the symptomatic treatment, and corticosteroid therapy which has 
      shown to improve patient outcomes.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
FAU - Neuzillet, Yann
AU  - Neuzillet Y
AD  - Universite de Versailles-Saint-Quentin-en-Yvelines, faculte de medecine 
      Paris-Ile-de-France-Ouest, hopital Foch, service d'urologie, Suresnes, France. 
      y.neuzillet@hopital-foch.org
FAU - Roupret, Morgan
AU  - Roupret M
FAU - Larre, Stephane
AU  - Larre S
FAU - Irani, Jacques
AU  - Irani J
FAU - Davin, Jean-Louis
AU  - Davin JL
FAU - Moreau, Jean-Luc
AU  - Moreau JL
FAU - Pfister, Christian
AU  - Pfister C
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Diagnostic et prise en charge des evenements indesirables severes survenant au 
      decours des instillations endovesicales de BCG pour le traitement des tumeurs de 
      vessie n'infiltrant pas le muscle (TVNIM).
DEP - 20130228
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (BCG Vaccine)
SB  - IM
MH  - Adjuvants, Immunologic/administration & dosage/*adverse effects
MH  - Administration, Intravesical
MH  - BCG Vaccine/*adverse effects/therapeutic use
MH  - Emergencies
MH  - Humans
MH  - Urinary Bladder Neoplasms/pathology/*therapy
EDAT- 2013/03/05 06:00
MHDA- 2013/09/10 06:00
CRDT- 2013/03/05 06:00
PHST- 2012/07/05 00:00 [received]
PHST- 2012/10/12 00:00 [revised]
PHST- 2012/10/23 00:00 [accepted]
PHST- 2013/03/05 06:00 [entrez]
PHST- 2013/03/05 06:00 [pubmed]
PHST- 2013/09/10 06:00 [medline]
AID - S0755-4982(13)00019-5 [pii]
AID - 10.1016/j.lpm.2012.10.017 [doi]
PST - ppublish
SO  - Presse Med. 2013 Jul-Aug;42(7-8):1100-8. doi: 10.1016/j.lpm.2012.10.017. Epub 
      2013 Feb 28.